Demography and mean SII in the study population and healthy controlsa
| Patients with MS, Baseline | Patients with MS, 9-Year Follow-Up | Patients with MS, 18-Year Follow-Up | Healthy Controls | |
|---|---|---|---|---|
| Female/male (No.) | 18:5 | 18:5 | 18:5 | 18:5 |
| Age (yr) | 39 ± 8.1 | 48 ± 8.1 | 57 ± 8.0 | 57 ± 7.2 |
| Disease duration (yr) | 10 ± 7 | 19 ± 7 | 27 ± 7 | – |
| MS subtype: RR/SP/PP (No.) | 18/5/0 | 13/10/0 | 3/20/0 | – |
| Disease-modifying therapy (No.) (%) | 13 (57%) | 13 (57%) | 5 (22%) | – |
| Gadolinium administrations (median) (range) | 1 (0–3) | 3 (2–10) | 6 (3–12) | 0 |
| Dentate nucleus SII, middle cerebellar peduncle as a reference | 1.01 ± 0.02 | 1.03 ± 0.03 | 1.06 ± 0.05 | 1.01 ± 0.03b |
| Globus pallidus SII, thalamus as a reference | 1.04 ± 0.05 | 1.06 ± 0.04 | 1.09 ± 0.06 | 1.10 ± 0.04c |
Note:—PP indicates primary-progressive; RR, relapsing-remitting; SP, secondary-progressive.
↵a Values are reported as means, unless otherwise specified.
↵b The difference in SIIs between controls and patients with MS: unpaired t test (P < .001).
↵c The difference in SIIs between controls and patients with MS: unpaired t test (P =.19).